Ventyx Biosciences Inc. (VTYX) is having quite the week. Shares of the biopharma company soared 62.59% to $16.34 in after-hours trading Tuesday after The Wall Street Journal reported that Eli Lilly & Co. (LLY) is in advanced talks to acquire the company for more than $1 billion.

According to the report, which cited people familiar with the matter, a deal could be announced any day now. Both Ventyx and Eli Lilly declined to comment on the reports.

What Ventyx Actually Does

Ventyx is a San Diego-based clinical-stage biotechnology company focused on developing oral therapies for inflammatory diseases. Think Crohn's disease, rheumatoid arthritis, and other conditions where your body's inflammatory response goes into overdrive. One of their drug candidates is currently in mid-stage clinical trials for cardiovascular disease connected to obesity, which makes it particularly interesting given the current market obsession with anything obesity-related.

The Science Behind the Deal

Here's where it gets interesting. Ventyx specializes in targeting NLRP3, a protein complex that plays a crucial role in the body's inflammatory response. This is an emerging category that's caught the attention of major pharmaceutical players, including Roche Holding (RHHBY) and Novo Nordisk (NVO), according to Jefferies analysts. For Lilly, acquiring Ventyx would significantly broaden its portfolio in both autoimmune diseases and obesity treatments, two massive markets where the Indianapolis-based pharma giant is already making big bets.

The Numbers Tell a Story

The stock's performance has been nothing short of remarkable. Before Tuesday's regular trading session even ended, Ventyx (VTYX) closed at $10.05, already up 28.52% for the day. The after-hours surge just piled on top of that. Looking at the bigger picture, the stock has skyrocketed 315.29% over the past 12 months, reflecting serious investor confidence even before acquisition rumors surfaced.

The Relative Strength Index currently sits at 60.68, suggesting the stock has room to run without being technically overbought. With a market capitalization of approximately $717.2 million, Ventyx's shares have traded in a wide range over the past year, from a 52-week low of $0.78 to a high of $25.00. At current levels, the stock is sitting about 38.3% of the way from its low to its high, meaning there's still substantial upside if it approaches those previous peaks.

The momentum metrics are equally impressive. Market data indicates Ventyx has strong momentum in the 99th percentile, putting it among the top performers in terms of price action and trading strength.

If the acquisition closes at over $1 billion, it would represent a significant premium over Ventyx's current market cap, explaining why investors are piling in. The question now is whether Lilly will seal the deal or if another bidder might emerge to compete for this promising biotech platform.